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P .007). This association was observed irrespective of the type of
GVHD prophylaxis given. There was no difference in chronic
GVHD (18/32 [56%] vs 43/77 [56%] in the mismatched and
matched cohorts, respectively; P  .99). Relapse rates were also
similar (49% vs 53%; P  .84). Actuarial 1-year OS was 56% for
the mismatched group and 54% for the matched cohort, with a
2-year OS of 40% and 35%, respectively (P .40). Among patients
mismatched at HLA-C, aGVHD incidence was 16/23 (70%), and
there was a signiﬁcant trend toward decreased 1 and 2-year survival
(45% and 22%, vs 60% and 44% in C-matched patients; P  .07).
There was no difference in relapse associated with HLA-C dispar-
ity. In Cox regression-adjusted for HLA-disparity, donor/recipient
age, gender disparity, stem cell source (BM vs PBSC), disease
status, and GVHD prophylaxis, there remained a trend toward
worse survival for patients mismatched at HLA-C (HR 2.1; P 
.09), and grade II-IV acute GVHD was the only statistically sig-
niﬁcant predictor of death (HR 4.7; P  .001). We conclude that
single antigen/allele mismatch in HLA-A, B, and DQ is permissi-
ble for URD NST, but HLA-C disparity should be treated with
caution.
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CONTRIBUTIONS OF KIR GENOTYPE AND HLA-C-ENCODED KIR LI-
GANDS TO THE OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM
CELL TRANSPLANTATION
Fischer, J.1; Ottinger, H.D.2; Ferencik, S.2; Schwan, M.A.1; Middleton,
P.G.3; Grosse-Wilde, H.2; Wernet, P.1; Dickinson, A.M.3; Uhrberg,
M.1 1. Institute for Transplantation Diagnostics and Cell Therapeutics,
Du¨sseldorf University, Du¨sseldorf, Germany; 2. Institute of Immunol-
ogy, University Hospital of Essen, Essen, Germany; 3. Department of
Haematology, School of Clinical and Laboratory Sciences, University of
Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom.
A hallmark of human natural killer cells is the expression of
killer-cell immunoglobulin-like receptors (KIR), which enable the
detection of changes in HLA class I expression. The KIR family is
highly polymorphic and characterized by interindividual dif-
ferences in the number of inherited genes, which vary from 7
to sometimes 14 different genes. The aim of this study was
to analyze the inﬂuence of KIR genes and HLA-encoded li-
gands on allogeneic SCT outcome. Statistical analyses of trans-
plantation outcomes in unrelated HLA-matched transplanta-
tion for chronic myeloid leukemia (CML; n  109) by
univariate and multivariate analyses exhibited a signiﬁcant inﬂu-
ence of HLA-C-encoded KIR epitopes on overall survival.
Whereas patients with 2 HLA-Casn80 allotypes (HLA-C group
1) had an overall survival (OS) at 6 years of 76%, patients with 1
or 2 HLA-Clys80 allotypes (HLA-C group 2) exhibited a sig-
niﬁcantly decreased OS of 54% (independent of transplant
source and disease status in logistic regression analysis). Among
the latter subgroup, those patients, who received a transplant from
a donor with 2 HLA-Clys80 allotypes had a substantially better
event-free survival (EFS  79%) than those who received a trans-
plant from a donor with 1 or 2 HLA-Casn80 allotypes (EFS 
40%). Next, generic typing for presence or absence of KIR genes
was employed to assess the contribution of KIR genotype on SCT
outcome. A subgroup of patients was deﬁned who received grafts
from donors with 1 additional stimulatory KIR gene compared to
the patient’s genotype (KIRS_D1). A beneﬁcial inﬂuence of the
KIRS_D1 constellation on OS was seen in the unrelated SCT
study described earlier, as well as in a related SCT study of
HLA-identical sibling donor transplantations (n  65). Moreover,
epistatic interaction was seen between KIR genes and HLA-C
epitopes; among the patients with 1 or 2 HLA-Clys80 allotypes,
the KIRS_D1 group performed signiﬁcantly better (OS  83%)
than the remaining patients (OS  47%). In summary, consider-
ation of donor/patient KIR genotypes in combination with patient-
encoded KIR ligands might lead to an improvement in donor
selection in SCT.
IMMUNE RECONSTITUTION
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THE GENERATION OF DONOR-DERIVED VIRUS-SPECIFIC CYTOTOXIC T
LYMPHOCYTES REACTIVE AGAINST CYTOMEGALOVIRUS AND ADENO-
VIRUS ANTIGENS FOR CLINICAL USE
Bollard, C.M.; Leen, A.; Huls, H.; Myers, G.D.; Sili, U.; Rooney, C.M.;
Helsop, H.E. Center for Cell and Gene Therapy, Baylor College of
Medicine, Houston, TX.
Cytomegalovirus (CMV) and adenovirus are major viral patho-
gens causing morbidity and mortality in immunocompromised
patients undergoing allogeneic stem cell transplantation. Previous
studies have shown that prophylactic adoptive immunotherapy
with donor-derived cytotoxic T lymphocytes (CTLs) directed
against Epstein-Barr virus (EBV) and CMV can effectively prevent
the clinical manifestations of these viruses. We have extended these
studies by generating CTLs from normal donor PBMCs that
should restore cellular immunity to both CMV and adenovirus
simultaneously. We have generated a clinical grade recombinant
adenovirus type 5 vector pseudotyped with a type 35 ﬁber
(Ad5f35pp65) carrying a transgene for the immunodominant CMV
antigen, pp65. We have developed a protocol using an initial round
of stimulation with autologous mononuclear cells transduced with
Ad5f35pp65, followed by 2 rounds of weekly stimulation with
autologous EBV-transformed lymphoblastoid cell lines (LCLs)
transduced with the same vector using MOIs of 10 and 100,
respectively. After 3 rounds of stimulation, 3 CTL cultures con-
tained a mean of 86% (range, 82%-95%) CD8ve and a mean of
9.5% (range, 5%-14%) CD4ve cells. Evaluable CTL lines
showed signiﬁcant cytotoxicity in chromium release assays against
autologous ﬁbroblasts and LCL infected with a CMV vector and
LCL infected with the Ad5GFP vector. The observed cytotoxicity
was speciﬁc because nontransduced LCLs, transduced and non-
transduced MHC-mismatched LCLs, and autologous PHA blasts
were not killed. ELISPOT assays on CTL demonstrated a mean of
459 (range, 284–634) and 497.5 (range, 402–593) numbers of cells
secreting interferon-gamma after stimulation with autologous
PBMC stimulated with CMV and adenovirus peptides, respec-
tively. Using MHC-peptide tetramers in a HLA-A2/B7ve donor
we have been able to demonstrate the simultaneous presence of
CD8ve cells recognizing peptide epitopes from CMV pp65
(range, 2.41%-9.08%) and adenovirus hexon (1.69%) in the CTL
culture. In summary, we have developed a protocol for the efﬁcient
generation ex vivo of CTL with virus speciﬁcity for CMV and
adenovirus. We are currently growing these CTL lines for clinical
use in a FDA-approved protocol to restore cellular immunity to
these viruses after allogeneic stem cell transplantation.
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ASPERGILLUS FUMIGATUS-SPECIFIC CYTOTOXIC T-CELL LINES GEN-
ERATED THROUGH USE OF ASP F16 PROTEIN-SPANNING POOLS OF
OVERLAPPING PENTADECAPEPTIDES
Ramadan, G.1; Davies, B.1; Kurup, V.P.2; Keever-Taylor, C.A.1 1.
Medical College of Wisconsin, Milwaukee, WI; 2. VA Medical Center,
Milwaukee, WI.
Invasive aspergillosis (IA) fungal infection is often lethal in im-
munosuppressed individuals, particularly patients undergoing
blood or marrow transplantation. Although ﬁrst-line defense
against IA is largely mediated by neutrophils and macrophages,
there is evidence that Th1 type T-cell response is essential in the
control of infection. We prepared 104 overlapping pentadecapep-
tides (11-aa overlap with previous peptide) spanning the coding
region of the aspergillus allergen, Asp f16, previously shown to
induce Th1-type cell responses in mice. These were used to prime
T-cell responses in healthy donors. PBMC from 5/5 donors pro-
liferated strongly to complete peptide pool (PPC)-pulsed autolo-
gous monocyte-derived dendritic cells (DC) generated by 2–3 days
of culture with GM-CSF and IL-4, pulsed, then matured for 2 days
with a cocktail of inﬂammatory cytokines. Cytotoxic T lymphocyte
(CTL) lines were generated from 2 donors by weekly priming of
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